Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CREST: Sasanlimab ± BCG vs BCG in High-Risk NMIBC and Sasanlimab in BCG-Unresponsive NMIBC
jRCT2071200044Phase 3Active, not recruiting
- Sponsor
- Pfizer
- Start
- Dec 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial of sasanlimab in bladder cancer and non-muscle-invasive bladder cancer (NMIBC) (5 cohorts), sponsored by Pfizer. Primary endpoints: Event-free survival (Cohort A Arm A vs Arm C), Complete response rate (Cohort B1) and 1 more. Started Dec 2020; status: active, not recruiting.
02
Drugs
sasanlimab
03
Conditions
bladder cancernon-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on jRCT2071200044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071200044.